Dana-Farber Cancer Institute: all 833 studies

Page 6 of 9. Open to participants first (121), then studies with results posted, then the rest; newest registration first within each.

• YES Study - Newly Diagnosed/Metastatic InterventionActive, not recruitingNCT04379414Not applicable
• SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer CareWithdrawnNCT04368130Not applicable
• Step Into Support for Endurance and Strength (SISTERS)CompletedNCT04354454Not applicable
• Phase I Study of Marizomib + Panobinostat for Children With DIPGTerminatedNCT04341311Phase 1
• Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate CancersCompletedNCT04330716Not applicable
• Intervention For Adolescents and Young Adults (AYAs) With Cancer Risk SyndromesActive, not recruitingNCT04323774Not applicable
• CIML NK Cell in Head & Neck CancerCompletedNCT04290546Phase 1
• GVAX Plus Checkpoint Blockade in NeuroblastomaTerminatedNCT04239040Phase 1
• Smart Phone App Intervention In Young Adults With CancerCompletedNCT04119869Not applicable
• Abemaciclib + Pembrolizumab In GlioblastomaWithdrawnNCT04118036Phase 2
• LY3214996 in Patients With AML Who Are Not Candidates for Standard TherapyCompletedNCT04081259Phase 1
• OPTimizing Treatment Focused Genetic Testing IN CancerCompletedNCT04066361Not applicable
• ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
• Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 OverexpressionWithdrawnNCT04040725Phase 2
• NeoVax With Nivolumab in Patients With Ovarian CancerActive, not recruitingNCT04024878Phase 1
• A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWithdrawnNCT04007588Phase 2
• Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsActive, not recruitingNCT03974217Phase 1
• Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric CancerCompletedNCT03936465Phase 1
• Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention PilotCompletedNCT03913936Not applicable
• Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for PainCompletedNCT03910296
• Personal Web Page In Clinical Trial Participant EducationCompletedNCT03887091Not applicable
• EHR-embedded OCDT in Breast or GI CancerCompletedNCT03858712Not applicable
• 'ADVANCE' (A Pilot Trial)Active, not recruitingNCT03858322Phase 1
• Tucatinib + Abemaciclib + Herceptin for HER2+ MBCWithdrawnNCT03846583Phase 1
• Yoga for Painful Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized-Controlled StudyCompletedNCT03824860Not applicable
• Elevate! : An Elderly Breast Cancer Cohort StudyActive, not recruitingNCT03818087
• A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)CompletedNCT03773666Phase 1
• GENetic Education Risk Assessment and TEsting StudyActive, not recruitingNCT03762590Not applicable
• Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation TherapyCompletedNCT03761160Not applicable
• Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast CancerCompletedNCT03749421
• Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALLActive, not recruitingNCT03740334Phase 1
• Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain GoalsCompletedNCT03736746Not applicable
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
• DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BCActive, not recruitingNCT03716180Phase 1
• Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AMLActive, not recruitingNCT03709758Phase 1
• Mindfulness-Music Intervention for Adolescents and Young Adults With CancerCompletedNCT03709225Not applicable
• AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine CarcinosarcomaActive, not recruitingNCT03668340Phase 2
• Physical Activity, Proliferation and Immune Markers in Benign Breast TissueActive, not recruitingNCT03657628Not applicable
• Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric CancerCompletedNCT03654716Phase 1
• Olaparib + Sapacitabine in BRCA Mutant Breast CancerActive, not recruitingNCT03641755Phase 1
• Niraparib in Patients With Pancreatic CancerCompletedNCT03601923Phase 2
• Osimertinib In EGFR Mutant Lung CancerActive, not recruitingNCT03586453Phase 2
• The GI Binder: A Psychoeducational Intervention for Gastrointestinal Cancer PatientsCompletedNCT03576872Not applicable
• Sexual Health and Rehabilitation After Ovarian Suppression TreatmentCompletedNCT03571841Not applicable
• Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and OutcomesCompletedNCT03532971
• Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic CancerTerminatedNCT03520790Phase 1
• Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral NeuropathyCompletedNCT03514680Not applicable
• A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid TumorsCompletedNCT03495323Phase 1
• Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)CompletedNCT03485547Phase 1
• Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse BackgroundsCompletedNCT03447886
• A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03392246Phase 2
• SHARE (Sharing Goals and Preferences) StudyCompletedNCT03392090Not applicable
• Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular LymphomaActive, not recruitingNCT03361852Phase 1
• HealthSmart: Promoting Healthy Lifestyles for Young Adult Cancer Survivors Using Educational VideosCompletedNCT03340532Not applicable
• Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsActive, not recruitingNCT03333616Phase 2
• Physical Activity In Gastrointestinal CancerCompletedNCT03331406Not applicable
• Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)CompletedNCT03328091Not applicable
• Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALLActive, not recruitingNCT03319901Phase 1/2
• Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic CancerCompletedNCT03316599Phase 1
• Ribociclib + PDR001 in Breast Cancer and Ovarian CancerTerminatedNCT03294694Phase 1
• A Nurse Led Project to Introduce Hand Lettering as a Form of Creative Art Expression to Patients in an Ambulatory Oncology SettingCompletedNCT03291730Not applicable
• Web-based Insomnia Treatment for Adolescent and Young Adult Cancer SurvivorsCompletedNCT03279055Not applicable
• Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerTerminatedNCT03277482Phase 1
• Post-Operative Ambulatory Challenge and Exercise (PACE) TrialCompletedNCT03234933Not applicable
• An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple MyelomaWithdrawnNCT03227432Phase 2
• Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerCompletedNCT03170206Phase 1
• A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2Active, not recruitingNCT03152318Phase 1
• Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)Status unknownNCT03141671Phase 2
• Cyclophosphamide and Alemtuzumab In LymphomaTerminatedNCT03132584Phase 1
• Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03122717Phase 1/2
• Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation TherapyCompletedNCT03070145Not applicable
• Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspendedNCT03065062Phase 1
• Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized TherapyActive, not recruitingNCT03060720
• Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsActive, not recruitingNCT03020030Phase 3
• Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition SyndromesActive, not recruitingNCT02950987Not applicable
• Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaCompletedNCT02909777Phase 1
• Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver MalignanciesWithdrawnNCT02853500Phase 4
• Qigong For PPSP In Breast Cancer Pain In Breast Cancer SurvivorsCompletedNCT02848989Not applicable
• Implementation of a System-level Tobacco Treatment InterventionCompletedNCT02816697Not applicable
• ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLActive, not recruitingNCT02787369Phase 1
• CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer SurvivorsCompletedNCT02756390Not applicable
• Evaluation Of Lymph Nodes After Neoadjuvant ChemotherapyWithdrawnNCT02752009Not applicable
• MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal CancerWithdrawnNCT02689401Phase 1
• Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple MyelomaNo longer availableNCT02666209
• GO-203-2C + Bortezomib For Relapsed Or Refractory MMWithdrawnNCT02658396Phase 1
• BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified TumorsWithdrawnNCT02656849Phase 2
• The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast CancerActive, not recruitingNCT02653755Phase 2
• Improving Surgical Decision-making in Young Women With Breast CancerCompletedNCT02644382
• Novel Social Media Intervention For Older Br CA PatientsCompletedNCT02639208Not applicable
• The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium StudyActive, not recruitingNCT02520713
• A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)CompletedNCT02502695
• The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle BiopsyCompletedNCT02489617Not applicable
• Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and NeckActive, not recruitingNCT02474368Phase 1
• Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer SurvivorsTerminatedNCT02452710Not applicable
• Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by CuldocentesisTerminatedNCT02441140Not applicable
• Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung CancerWithdrawnNCT02423148Not applicable
• Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone MetsCompletedNCT02406521Phase 1
• Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone FractureCompletedNCT02355340
• Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving TherapyCompletedNCT02335671Not applicable
• Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHDCompletedNCT02318082Phase 1

← Dana-Farber Cancer Institute overview and focus areas